Trans Genic Inc. (2342.T)
JPY 181.0
(0.56%)
JPY 181.0
(0.56%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 240.95 Million JPY | 91.26% |
| 2022 | -119.83 Million JPY | -93.07% |
| 2021 | 3.01 Billion JPY | 77.13% |
| 2020 | 975.05 Million JPY | 189.69% |
| 2019 | 2.41 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -64.75 Million JPY | -219.17% |
| 2023 Q2 | -22.91 Million JPY | -116.49% |
| 2023 FY | - JPY | 91.26% |
| 2023 Q3 | -46.64 Million JPY | -103.53% |
| 2023 Q1 | 138.94 Million JPY | 189.33% |
| 2023 Q4 | 54.33 Million JPY | 216.5% |
| 2022 Q3 | 65.3 Million JPY | -67.19% |
| 2022 FY | - JPY | -93.07% |
| 2022 Q4 | -155.54 Million JPY | -338.19% |
| 2022 Q2 | 199.05 Million JPY | 0.0% |
| 2021 FY | - JPY | 77.13% |
| 2020 FY | - JPY | 189.69% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 74.851% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | 149.362% |
| GNI Group Ltd. | 14.48 Billion JPY | 98.337% |
| Linical Co., Ltd. | 1.24 Billion JPY | 80.681% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 117.771% |
| Soiken Holdings Inc. | -583.2 Million JPY | 141.315% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | 139.953% |
| AnGes, Inc. | -8.86 Billion JPY | 102.72% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 118.744% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 103.257% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | -88.087% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 127.92% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 122.07% |
| CanBas Co., Ltd. | 53.65 Million JPY | -349.11% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 131.067% |
| RaQualia Pharma Inc. | -111.8 Million JPY | 315.519% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 119.885% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 117.45% |
| PeptiDream Inc. | 7.37 Billion JPY | 96.733% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 112.487% |
| Ribomic Inc. | -1.01 Billion JPY | 123.797% |
| SanBio Company Limited | -4.52 Billion JPY | 105.325% |
| Healios K.K. | -3 Billion JPY | 108.013% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 120.669% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 117.296% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 117.186% |
| StemRIM | -2.03 Billion JPY | 111.858% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 81.557% |
| FunPep Company Limited | -952 Million JPY | 125.31% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 127.111% |
| Stella Pharma Corporation | -723.85 Million JPY | 133.287% |
| TMS Co., Ltd. | -937 Million JPY | 125.715% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 131.075% |
| Cuorips Inc. | -518 Million JPY | 146.516% |
| K Pharma,Inc. | 366.05 Million JPY | 34.177% |
| Takara Bio Inc. | 8.02 Billion JPY | 96.997% |
| ReproCELL Incorporated | 8.24 Million JPY | -2822.401% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | -174.002% |
| StemCell Institute Inc. | 534.35 Million JPY | 54.908% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 1.578% |
| CellSeed Inc. | -836.51 Million JPY | 128.804% |